Hansoh Pharmaceutical (03692.HK): NMPA Accepts New Drug Application for Orlotide Injection
NewTimeSpace News: On June 4, 2026, Hansoh Pharmaceutical (03692.HK) issued a voluntary announcement, disclosing that on June 3, 2026, the marketing authorization application for its in-house innovative product Orlotide Injection was accepted by the National Medical Products Administration (NMPA). The indication covers long-term weight management for adult patients with obesity or overweight.
Orlotide is a once-weekly dual agonist targeting GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Hansoh Pharmaceutical (03692.HK): Enters Licensing and Equity Investment Transaction with Avere Therapeutics
- HANSOH PHARMA (03692.HK): Refiles EU Marketing Application for Aumseqa
- Hansoh(03692.HK): EU revokes Aumolertinib approval, EMA resubmission planned
- HANSOH PHARMA (03692.HK): NMPA Accepts NDA for HS-20093, Its B7-H3-Targeting ADC, in Osteosarcoma
- HANSOH PHARMA (03692.HK): HS-20093 Gets Osteosarcoma Priority Review
